Dallas, Texas 10/31/2013 (Financialstrend) - On October 30 Cell Therapeutics (NASDAQ:CTIC) reported its results from 3Q operations. The $192 million market capitalized drug maker had managed to post loss per share of $0.2. This was $0.03 more than what analysts were predicting. It was also able to generate revenue...
Dallas, Texas 11/19/2013 (Financialstrend) - In Monday’s trading session, Synta Pharmaceuticals Corp. (NASDAQ:SNTA) rose by 15.15%. The shares opened at a price of $4.45, which touched the intraday high of $5.20 and headed to a close of $4.87. Around 6.08 million exchanged hands over the trading day and an average...
CONVALO HEALTH INTERNATIONAL CORP (CVE:CXV) a major firm in the United States addiction recovery segment, released its financial statements for the quarter and nine months closed November 2016 on SEDAR. The firm is a leader in the market of addiction rehabilitation. It has operated since 2014, when it bought...
Dallas, Texas 07/15/2013 (Financialstrend) - Pfizer, Inc. (NYSE:PFE)  obtained approval from the U.S. Food and Drug Administration (FDA) for the company’s Eliquis® (apixaban), a Factor Xa inhibitor, which is used to prevent venous thromboembolic events (VTE) in adult patients for those who had undergone surgery related to elective hip or knee...
Dallas, Texas 03/19/2014 (FINANCIALSTRENDS) –  Antares PharmaInc (NASDAQ:ATRS) which is just celebrating its better-than-expected fourth quarter results and full year financial results, has fallen into a legal hassle, with Chicago-based  Medac Pharma Inc, a subsidiary of Germany-based medacGesellschaftfürklinischeSpezialpräparatembH filing a patent violation. The issue is related to a recently approved patent...
Dallas, Texas 03/20/2014 (FINANCIALSTRENDS) –  ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Los Angeles-based clinical stage company engaged in developing immune-based therapies for brain and other cancer treatments, recently declared its financial results for the fourth quarter and full year ended December 31, 2013. The company reported a fourth quarter net income of...
Boston, MA - (Financialstrend) - 03/24/2014 – Novavax, Inc (NASDAQ:NVAX) announced the execution of a certain contract modification for extension of the base-period of performance of the company’s current contract with the United States Department of Health & Human Services & Biomedical Advanced Research & Development Authority for advanced development of Novavax, Inc (NASDAQ:NVAX)’s recombinant seasonal...
Signal Genetics Inc (NASDAQ:SGNL) a molecular genetics diagnostic firm in it commercial stage and focused on offering innovative diagnostic services to help physicians take better-informed decisions updated on recent achievements and financial performance for 3Q2015. The details Tests billed for hospitals in the United States and other direct billed clients outside...
XBiotech Inc. (NASDAQ:XBIT) stock had a weekly volatility of 65.32% and a monthly volatility of 22.53%. XBiotech Inc. XBIT shares float stands at 19.26M. The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is...
Dallas, Texas 10/17/2013 (Financialstrend) - The development stage biotech and drug manufacturing firm MannKind Corporation (NASDAQ:MNKD) has filed an update with SEC listing out details of the reworked new drug application it has filed with U.S. Food and Drug Administration. The NDA is for target drug called Afrezza. The application...

Subscribe to our mailing list

* indicates required

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play